Stockreport

Edgewise Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

Edgewise Therapeutics, Inc.  (EWTX) 
PDF – Overenrolled CANYON and advanced the global pivotal cohort, GRAND CANYON, of EDG-5506 in Becker muscular dystrophy (Becker) –– Advanced Phase 2 LYNX trial of EDG-5506 [Read more]